Distribution of IL28B genotypes in Iranian patients with chronic hepatitis C and healthy individuals

Hepatitis Monthly

Volumn 12, Issue 12, 2012, Pages

  Sharafi, Heidar ^a,b   Pouryasin, Ali ^a,b,c   Alavian, Seyed Moayed ^b,d   Behnava, Bita ^b,d   Keshvari, Maryam ^b,e   Salimi, Shima ^b,d   Mehrnoush, Leila ^b,d   Fatemi, Ahmad ^f  

^a Armin Pathobiology Laboratory   (Iran)

^b Tehran Hepatitis Cohort (THC) Study   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Genetic; Hepatitis C; Human; IL28B Genotype; Iran; Persian Gulf; Polymorphism

Indexed keywords

INTERLEUKIN 28;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84872331059     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.8387     Document Type: Article

References (19)

1. Dehesa-Violante M, Nunez-Nateras R. Epidemiology of hepatitis virus B and C. Arch Med Res. 2007;38(6):606-11.
2. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. JViral Hepat. 2006;13(1):34-41.
3. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20(1):17-35.
4. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-93.
5. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):39 9-401.
6. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338-45, 45 e1-7.
7. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;4l(10):1100-4.
8. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;4l(10):1105-9.
9. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;46l(7265):798-801.
10. Sibbing B, Nattermann J. Hepatitis C virus infection and genetic susceptibility to therapy. J Gastrointestin Liver Dis. 2011;20(4):397-406.
11. Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, Cmet S, et al. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol. 2011;3l(5):891-9.
12. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, Romero-Go-mez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010;52(1):33-7.
13. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Meh-rnoush L, et al. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. Hepat Mon. 2010;12(3):190-5.
14. McHutchison JG. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care. Liver Int. 2011;3l:29-35.
15. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138(7):2307-14.
16. Pedergnana V, Abdel-Hamid M, Guergnon J, Mohsen A, Le Fouler L, Theodorou I, et al. Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus. PLoS One. 2012;7(6):e38578.
17. Thomson EC, Fleming VM, Main J, Klenerman P, Weber J, Eliahoo J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. 2011;60(6):837-45.
18. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Aliment Pharmacol Ther. 2012;36(2):91-103.
19. Schreiber J, Moreno C, Garcia BG, Louvet A, Trepo E, Henrion J, et al. Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and-3 patients. Aliment Pharmacol Ther. 2012;36(4).